



I'm not robot



**Continue**


## Board basics 18 pdf

### Basic education requirements.


In these pages, you will find essential facts and strategies for passing the Internal Medicine Certification and Maintenance Certification Examinations. Effective for both certification and re-certification. Keep this indispensable resource at your side as you get closer to your exams. This book is known for popular features such as: – Examples of incorrect answers that masquerade as correct choices – Test yourself abbreviated case histories – Study tables that summarize important concepts GET IT FREE HERE ALTERNATIVE LINK health care goods or services consumed by, or used on, patients. Contributors are required to use generic names in the discussion of therapeutic options and are required to identify any unapproved, off-label, or investigative use of commercial products or devices. Where a trade name is used, all available trade names for the same product type are also included. If trade-name products manufactured by companies with whom contributors have relationships are discussed, contributors are asked to provide evidence-based citations in support of the discussion. [timber\\_rattlers\\_schedule.pdf](#) The information is reviewed by the committee responsible for producing this text. [nitro\\_editor\\_with\\_crack\\_download.pdf](#) If necessary, adjustments to topics or contributors' roles in content development are made to balance the discussion. Further, all readers of this text are asked to evaluate the content for evidence of commercial bias and send any relevant comments to [email protected] so that future decisions about content and contributors can be made in light of this information. The ACP will consider granting an individual permission to reproduce only limited portions of this publication for his or her own exclusive use. Send requests in writing to MKSAP® Permissions, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106-1572, or email your request to [email protected]. MKSAP 18 ISBN: 978-1-938245-47-3 (Board Basics) ISBN: 978-1-938245-73-2 Printed in the United States of America. For order information in the U.S. or Canada call 800-ACP1915. All other countries call 215-351-2600 (Monday to Friday, 9 AM – 5 PM ET). Fax inquiries to 215-351-2799 or email to [help@acponline.org](mailto:help@acponline.org). Testing Stress testing is most useful in patients with an intermediate pretest probability of CAD (>10% or Indications Exercise ECG without imaging Patients who can exercise Exercise ECG with myocardial perfusion imaging or exercise echocardiography Patients who can exercise Normal or nonspecific baseline ECG changes (e.g., 1 mm ST depression Previous CABG or PCI LBBB LV hypertrophy Digoxin use Pharmacologic stress myocardial perfusion imaging or dobutamine echocardiography Unable to exercise Electrically paced ventricular rhythm LBBB aCTA can detect anatomic coronary abnormalities (compared with functional ischemia on stress testing) and has been shown to be effective in the assessment of patients with suspected CAD. Select coronary angiography for patients with high pretest probability of disease or: • LV dysfunction • class III or IV angina despite therapy • highly positive stress or imaging test • high pretest probability of left main or three-vessel CAD (a Duke treadmill score  $\leq -11$ ) • uncertain diagnosis after noninvasive testing • history of surviving sudden cardiac death • suspected coronary spasm DON'T BE TRICKED • Stress testing is of little value in patients with very low (e.g., 90%) pretest probabilities of CAD. • In patients with LBBB, do not perform exercise ECG for evaluation of possible CAD; stress echocardiography or vasodilator stress radionuclide myocardial perfusion imaging should be performed instead. [amoeba\\_sisters\\_intro\\_to\\_cells\\_worksheet](#) 6 This document is licensed for individual use only. Copyright © 2018 American College of Physicians. All rights reserved.

Cardiovascular Medicine Treatment Intensive lifestyle modification is selected for all patients with chronic stable angina. Treatment is indicated to achieve the following goals: BP DON'T BE TRICKED • Do not select hormone replacement therapy (in women), antioxidant vitamins (vitamin E), or treatment of elevated serum homocysteine levels with folic acid or vitamin B12. TEST YOURSELF A 69-year-old man has burning retrosternal discomfort related to exertion. [accu\\_check\\_aviva\\_error\\_codes.pdf](#) His father died of an acute MI at age 61 years. Physical examination is unremarkable, and the resting ECG is normal. ANSWER: For treatment, choose aspirin, sublingual nitroglycerin, and a  $\beta$ -blocker, and follow up with an exercise stress test. Heart Failure Diagnosis One half of patients with HF have HF with preserved ejection fraction (HFpEF), the remainder have HF with reduced ejection fraction (HFrEF). Patients with HFrEF often have dilated ventricles and patients with HFpEF have normal systolic contraction and normal-sized ventricles or concentric hypertrophy. Symptoms are the same for HFrEF and HFpEF. 7 This document is licensed for individual use only. Copyright © 2018 American College of Physicians. All rights reserved. Cardiovascular Medicine Symptoms and signs that increase the likelihood of HF as a diagnosis include: • paroxysmal nocturnal dyspnea (>2-fold likelihood) • an S3 (11-fold likelihood) The likelihood of HF as a diagnosis is decreased 50% by: • absence of dyspnea on exertion • absence of crackles on pulmonary auscultation Disease classification systems are part of the diagnosis and can help guide treatment decisions. STUDY TABLE: NYHA Classification of Heart Failure NYHA Functional Class I (structural disease but no symptoms) II (symptomatic; slight limitation of physical activity) III (symptomatic; marked limitation of physical activity) IV (inability to perform any physical activity without symptoms) Testing A BNP level >400 pg/mL is compatible with HF, and a level DON'T BE TRICKED • Routine testing for unusual causes of HF, including hemochromatosis, Wilson disease, multiple myeloma, and myocarditis, should not be performed. [elt\\_first\\_year\\_books.pdf](#) • Don't order serial BNP in hospitalized patients to monitor HF. [94417068577.pdf](#) • Kidney failure, older age, and female sex all increase BNP; obesity reduces BNP. Treatment of HFrEF For making treatment decisions, NYHA functional classification can be implemented. [ball\\_pool\\_unlocked\\_games\\_google\\_sites\\_STUDY\\_TABLE](#): Treatment of HFrEF Therapy Indication ACE inhibitors For all stages of HF to reduce mortality ARBs are acceptable if ACE inhibitor cannot be tolerated Hydralazine plus nitrates Given in addition to standard therapy for NYHA class III-IV and EF  $\geq 50\%$  This document is licensed for individual use only. Copyright © 2018 American College of Physicians. All rights reserved. Cardiovascular Medicine STUDY TABLE: Treatment of HFrEF (Continued) Therapy Indication  $\beta$ -Blockers (only metoprolol succinate, carvedilol, and bisoprolol) For NYHA classes I-IV to reduce mortality Aldosterone antagonist (spironolactone or eplerenone) For NYHA class III-IV HF to reduce mortality Digitalis Used predominantly in patients who continue to experience symptoms despite guideline-directed medical therapy Diuretics Given to improve symptoms of volume overload (襚radine EF  $\leq 35\%$  who are in sinus rhythm with a heart rate  $\geq 70$ /min Valsartan-sacubitril Substitute for an ACE inhibitor or ARB in HFrEF (NYHA class II or III) in patients who have tolerated ACE inhibitor or ARB therapy ICD For ischemic and nonischemic cardiomyopathy in patients with an EF  $\leq 35\%$  and NYHA functional class II-III or with an EF  $\leq 30\%$  and NYHA functional class I For NYHA class II-III symptoms Cardiac resynchronization therapy For NYHA class II-IV, LVEF  $\leq 35\%$ , and LBBB with QRS duration >150 ms Cardiac transplantation For patients with refractory HF symptoms despite maximal medical therapy Exercise training Recommended in all patients with newly diagnosed HF DON'T BE TRICKED • Do not begin  $\beta$ -blocker therapy in patients with decompensated HF. • Continuous IV infusion of furosemide provides no advantage vs. bolus therapy in decompensated HF. • Do not prescribe or continue NSAIDs or thiazolidinediones because they worsen HF. • Nondihydropyridine calcium channel blockers (diltiazem or verapamil) may be harmful to patients with HF. TEST YOURSELF A 64-year-old woman with previously stable HF now has increasing orthopnea.

Medications are lisinopril 10 mg/d and furosemide 20 mg/d. BP is 140/68 mm Hg and HR is 102/min. Pulmonary crackles and increased JVD are present. ANSWER: For treatment, increase the furosemide and lisinopril dosages and add a  $\beta$ -blocker when the patient is stable. Follow-Up In patients with chronic HF who are clinically stable, follow-up echocardiography more frequently than every 1 to 2 years is not recommended. Heart Failure with Preserved Ejection Fraction Diagnosis HFpEF (also known as diastolic HF) when signs and symptoms of HF are present but the echocardiogram reveals EF >50% and significant valvular abnormalities are absent. Treatment of HFpEF The primary treatment goals in HFpEF are to treat the underlying cause (hypertension, AF), to manage potentially exacerbating factors (e.g., tachycardia), and to optimize diastolic filling (control HR and avoid decreased effective circulating blood volume). Diuretics should be used when volume overload is present. 9 This document is licensed for individual use only.




Copyright © 2018 American College of Physicians. All rights reserved. Cardiovascular Medicine DON'T BE TRICKED • Pharmacologic agents ( $\beta$ -blockers, ACE inhibitors, ARBs, aldosterone antagonists) have not been shown to decrease morbidity and mortality in patients with HFpEF. Nonischemic Dilated Cardiomyopathy Diagnosis Dilated cardiomyopathy is characterized by dilation and reduced function of one or both ventricles manifesting as HF, arrhythmias, and sudden death. The most common cause is idiopathic dilated cardiomyopathy (50%), but the differential diagnosis is broad. STUDY TABLE: Differential Diagnoses of Nonischemic Dilated Cardiomyopathy Condition Distinguishing Characteristics Acute myocarditis Associated with bacterial, viral, and parasitic infections and autoimmune disorders. Cardiac troponin levels are typically elevated; ventricular dysfunction may be global or regional. Can cause cardiogenic shock and ventricular arrhythmias. Choose supportive care in the acute phase, then standard HF therapy. Alcoholic cardiomyopathy Associated with chronic heavy alcohol ingestion, but other manifestations of chronic alcohol abuse may be absent. Typically, the LV (and frequently both ventricles) is dilated and hypokinetic. Choose standard HF therapy and total abstinence from alcohol. Drug-induced cardiomyopathy Illicit use of cocaine and amphetamines has been associated with myocarditis and dilated cardiomyopathy, as well as MI, arrhythmia, and sudden death. Choose standard HF treatment. In patients with stimulant-induced acute myocardial ischemia,  $\beta$ -blockers may exacerbate coronary vasoconstriction; labetalol, a  $\beta$ -blocker with  $\alpha$ -blocker activity, is preferred. Giant cell myocarditis Rare disease characterized by biventricular enlargement, refractory ventricular arrhythmias, and rapid progression to cardiogenic shock in young to middle-aged adults. [intercultural\\_communication\\_in\\_contexts\\_6th\\_edition.pdf](#) Histologic examination demonstrates the presence of multinucleated giant cells in the myocardium. Choose immunosuppressant treatment and/or LVAD placement or cardiac transplantation. Hemochromatosis Caused by excess iron deposition in the myocardium. Characterized by symptoms of heart failure and by conduction defects. Peripartum cardiomyopathy Presence of HF with an LVEF Stress-induced (takotsubo) cardiomyopathy Characterized by acute LV dysfunction in the setting of intense emotional or physiologic stress. May mimic acute STEMI. [the\\_secret\\_principles\\_of\\_genius\\_book.pdf](#) Dilated and akinesis of the LV apex occur in the absence of CAD. Resolves in days to weeks with supportive care. Tachycardia-mediated cardiomyopathy Occurs when myocardial dysfunction develops as a result of chronic tachycardia. [excel\\_monthly\\_budget\\_template\\_uk](#) Primary treatment is to slow or eliminate the arrhythmia. Treatment in addition to reversal of the underlying cause (alcohol, drug, and tachycardia-mediated cardiomyopathies), if possible, choose standard medical therapy for HF. TEST YOURSELF A 35-year-old man develops abdominal discomfort and swelling in both legs. He has an 18-pack-year smoking history and drinks a six-pack of beer daily but has no other significant medical history. Physical examination shows an elevated JVD, a displaced apical impulse, distant heart sounds, a grade 2/6 apical holosystolic murmur, an enlarged and tender liver, and peripheral edema.



ANSWER: For diagnosis, choose alcoholic cardiomyopathy. For management, select echocardiography and alcohol cessation. 10 This document is licensed for individual use only. Copyright © 2018 American College of Physicians. All rights reserved. Cardiovascular Medicine Hypertrophic Cardiomyopathy Diagnosis HCM is an uncommon primary cardiac disease characterized by diffuse or focal myocardial hypertrophy. The disease is genetically inherited in an autosomal dominant pattern in approximately 60% of patients. Patients may present with syncope (often arrhythmic), exertional syncope, or syncope associated with volume depletion, chest pain, and sudden cardiac death. STUDY TABLE: Distinguishing HCM from AS Assessment/Finding HCM AS Carotid pulse Rises briskly, then declines, followed by a second rise (pulsus bisferiens) Rises slowly and has low volume (pulsus parvus et tardus) Ejection sound None Present Aortic regurgitation None May be present Valsalva maneuver Increased murmur intensity No change or decreased murmur intensity Squatting to standing position Increased murmur intensity Decreased murmur intensity Carotid radiation None Usually present Apex beat "Triple ripple" Sustained single Testing The ECG shows LV hypertrophy and left atrial enlargement. Deeply inverted, symmetric T waves in leads V3-V6 are present in the apical hypertrophic form of the disease (mimics ischemia). Echocardiography is the diagnostic technique of choice. Treatment Patients with HCM should avoid competitive sports and intense isometric exercise.  $\beta$ -Blockers are first-line agents for patients with an EF  $\geq 50\%$ , dyspnea, and/or chest pain. Calcium channel blockers (verapamil or diltiazem) may be substituted for  $\beta$ -blockers. ACE inhibitors are used only if systolic dysfunction is present. Treat all patients with HCM and AF with warfarin (first line) or one of the NOACs (dabigatran, rivaroxaban, apixaban) (second-line therapy) regardless of CHA2DS2-VASc score. Surgery or septal ablation is indicated for patients with an outflow tract gradient of >50 mm Hg and continuing symptoms despite maximal drug therapy. Patients at high risk for sudden death (one or more major risk factors) are candidates for an ICD (see Study Table following). [florida\\_booster\\_education\\_temporary\\_certificate\\_test\\_answers](#) The absence of any risk factors has a high negative predictive value (>90%) for sudden death. STUDY TABLE: Sudden Death Risk Factors in HCM Major Risk Factors Previous cardiac arrest Spontaneous sustained VT Family history of sudden death (first-degree relative) Unexplained syncope LV wall thickness  $\geq 30$  mm Blunted increase or decrease in SBP with exercise Non-sustained spontaneous VT  $\geq 3$  beats DON'T BE TRICKED • Electrophysiologic studies are not useful in predicting sudden cardiac death. • Do not prescribe digoxin, vasodilators, or diuretics, which increase LV outflow obstruction, for patients with HCM. 11 This document is licensed for individual use only. Copyright © 2018 American College of Physicians. All rights reserved. Cardiovascular Medicine Screening All first-degree relatives of patients with HCM should have genetic counseling and, in the absence of a documented genetic mutation in the proband, echocardiographic screening. [zenezoloviorukubud.pdf](#) Ongoing screening is recommended throughout adulthood starting at age 12 years because of the possibility of disease expression at any age. Hypertrophic Cardiomyopathy: The ECG shows ST-segment depression and deeply inverted T waves (arrows) in the precordial leads consistent with marked apical hypertrophy.

Restrictive Cardiomyopathy Diagnosis In restrictive cardiomyopathy, abnormally rigid ventricular walls cause diastolic dysfunction in the absence of systolic dysfunction, manifesting as impaired ventricular filling and elevated diastolic ventricular pressures. Pulmonary venous congestion, PH, and right-sided HF ensue. Jugular veins may engorge with inspiration (Kussmaul sign). Testing Echocardiogram shows normal ejection fraction/systolic function. Cardiac catheterization shows elevated LV and RV enddiastolic pressures and a characteristic early ventricular diastolic dip and plateau. STUDY TABLE: Clues to Underlying Systemic Diseases Causing Restrictive Cardiomyopathy Disease Clues Amyloidosis Neurotomy, proteinuria, hepatomegaly, periorbital ecchymosis, bruising, low-voltage ECG. Diagnosis can be confirmed with abdominal fat pad aspiration. Sarcoidosis Bilateral hilar lymphadenopathy; possible pulmonary reticular opacities; and skin, joint, or eye lesions. Cardiac involvement is suggested by the presence of arrhythmias, conduction blocks, or HF. Diagnosis is supported by CMR imaging with gadolinium. Hemochromatosis Abnormal aminotransferase levels, OA, diabetes, erectile dysfunction, and HF; elevated serum ferritin and transferrin saturation level. Restrictive cardiomyopathy must be differentiated from constrictive pericarditis (see Cardiac Tamponade and Constrictive Pericarditis). 12 This document is licensed for individual use only. [79964403760.pdf](#) Copyright © 2018 American College of Physicians. [viper\\_5706v\\_installation\\_guide](#) All rights reserved. Cardiovascular Medicine Treatment Treat any underlying disease that affects diastolic function (hypertension, diabetes, ischemic heart disease, amyloidosis). [gitek.pdf](#) Loop diuretics are used to treat dyspnea and peripheral edema.  $\beta$ -Blockers or nondihydropyridine calcium channel antagonists may enhance diastolic function and should be considered if diuretic therapy is not effective or in the presence of atrial tachyarrhythmias. ACE inhibitors and ARBs may improve diastolic filling and may be beneficial in patients with diastolic dysfunction. TEST YOURSELF A 63-year-old man develops dyspnea and fatigue.



Physical examination shows JVD, a prominent jugular a wave, a prominent S4, and a grade 2/6 holosystolic murmur at the left sternal border. The lungs are clear. Other findings include an enlarged, tender liver; petechiae over the feet; and periorbital ecchymoses. ANSWER: The diagnosis is amyloid cardiomyopathy, indicated by the noncardiac symptoms and signs. Cardiac Amyloidosis: The ECG shows low voltage, the most common ECG abnormality associated with cardiac amyloidosis. [53474160574.pdf](#) Palpitations and Syncope Testing In a patient with palpitations and syncope, the key diagnostic test is an ECG recorded during the clinical event. Obtain an echocardiogram in patients with suspected structural heart disease. See General Internal Medicine chapter for major causes of syncope. STUDY TABLE: Diagnostic Studies for Suspected Arrhythmias Diagnostic Test Utility Advantages Limitations Resting ECG Initial diagnostic test in all patients Diagnostic if recorded during the arrhythmia Most arrhythmias are intermittent and not recorded on a resting ECG Ambulatory (24-hour) ECG Indicated for frequent (at least daily) arrhythmias Records every heart beat during a 24-hour period Not helpful if arrhythmia is infrequent (Continued on the next page) 13 This document is licensed for individual use only. Copyright © 2018 American College of Physicians. All rights reserved. Cardiovascular Medicine STUDY TABLE: Diagnostic Studies for Suspected Arrhythmias (Continued) Diagnostic Test Utility Advantages Limitations Exercise ECG Indicated for arrhythmias provoked by exercise Allows diagnosis of exercise-related arrhythmias Physician supervision required Event monitor Indicated for infrequent arrhythmias >1-2 min in duration Small recorder is held to the chest when symptoms are present Limited to symptomatic brief arrhythmias Saves previous 30 s to 2 min ECG signal when patient activates the recorder; can be activated following syncopal event to capture arrhythmia ECG leads limit patient activities Implanted recorder Indicated for very infrequent arrhythmias Long-term continuous ECG monitoring Invasive procedure with some risk Electrophysiology study Can be used for inducing, identifying, and clarifying mechanism of arrhythmia as well as for treatment (e.g., catheter ablation); EP studies are not used for initial diagnosis The origin and mechanism of an arrhythmia can be precisely defined Invasive procedure with some risk Sinus Bradycardia and Heart Block Diagnosis Sinus bradycardia occurs when the AV nodal impulses fire at a rate lower than expected (less than 60/min). Common causes are medications, hypothyroidism, and inferior MI. AV nodal block results from functional or structural abnormalities at the AV node or in the His-Purkinje system. Potentially reversible causes include acute or chronic myocardial ischemia, Lyme disease, sarcoidosis, and amyloidosis.



































magnetic resonance (imaging) CMV cytomegalovirus CNS central nervous system COPD chronic obstructive pulmonary disease CPP calcium phosphate CPPD calcium phosphate deposition CRAO central retinal arterial occlusion 405 This document is licensed for individual use only. Copyright © 2018 American College of Physicians. All rights reserved. Abbreviations CRP CRVO CSF CT CTA CTEPH C-reactive protein central retinal vein occlusion cerebrospinal fluid computed tomography computed tomography angiography computed tomography angiography catheter thromboembolic pulmonary hypertension CUP carcinoma of unknown primary CVA cerebrovascular accident CVID common variable immunodeficiency CVP central venous pressure DASH Dietary Approaches to Stop Hypertension DAT direct antiglobulin test DBP diastolic blood pressure DCIS ductal carcinoma in situ DDAVP 1-deamino-8-D-arginine vasopressin DEXA dual energy x-ray absorptiometry DHEAS dehydroepiandrosterone sulfate DI diabetes insipidus DIC disseminated intravascular coagulation DIP distal interphalangeal DISH diffuse idiopathic skeletal hyperostosis diabetic ketoacidosis DKA diffuse large B-cell lymphoma DLBCL diffusing capacity of lung for carbon monoxide Dlco DMARD disease-modifying antirheumatic drug DNA deoxyribonucleic acid DPLD diffuse parenchymal lung disease DRESS drug reaction with eosinophilia and systemic symptoms DVT deep venous thrombosis EBV Epstein-Barr virus ECG electrocardiogram EDTA ethylenediaminetetraacetic acid EE eosinophilic esophagitis EEG electroencephalogram ejection fraction EF EGD esophagogastroduodenoscopy epidermal growth factor receptor EGFR eGFR estimated glomerular filtration rate EHEC enterohemorrhagic Escherichia coli O157:H7 EIA enzyme immunoassay ELISA enzyme-linked immunosorbent assay EM erythema multiforme EMG electromyography EN erythema nodosum ENT ear, nose and throat ERCP endoscopic retrograde cholangiopancreatography ESR erythrocyte sedimentation rate FDA Food and Drug Administration FENA fractional excretion of sodium FEPO4 fractional excretion of filtered phosphate FEUrea fractional excretion of urea FEV1 forced expiratory volume exhaled in 1 second FFP fresh frozen plasma FIT fecal immunochemical test FMP familial Mediterranean fever FNAB fine-needle aspiration biopsy FOBT fecal occult blood testing FOLFIRI 5-fluorouracil, leucovorin, and irinotecan FOLFIRINOX 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin FOLFLOX 5-fluorouracil, leucovorin, and oxaliplatin FSH follicle-stimulating hormone FTA-ABS fluorescent treponemal antibody absorption test FVC forced vital capacity G6PD glucose 6-phosphate dehydrogenase GAD65 glutamate decarboxylase antibody GBM glomerular basement membrane GE gastroesophageal GERD gastroesophageal reflux disease GFR glomerular filtration rate GH growth hormone GI gastrointestinal GN glomerulonephritis GnRH gonadotropin-releasing hormone GP glycoprotein GU genitourinary GVHD graft-versus-host disease HACE high-altitude cerebral edema HAI high-altitude illness HAP hospital-acquired pneumonia HAPB high-altitude periodic breathing HAPE high-altitude pulmonary edema HAV hepatitis A virus HBsAg hepatitis B e antigen HBcG hepatitis B immune globulin hepatitis B surface antigen HBsAg HBV hepatitis B virus HCC hepatocellular carcinoma hCG human chorionic gonadotropin HCM hypertrophic cardiomyopathy HCV hepatitis C virus HELLP hemolysis, elevated liver enzyme levels, and a low platelet count HES hyperesinophilic syndromes HF heart failure HFpEF heart failure with preserved ejection fraction HFrEF heart failure with reduced ejection fraction HGA human granulocytic anaplasmosis HIDA hepatobiliary iminodiacetic acid HIPAA Health Insurance Portability and Accountability Act HIT heparin-induced thrombocytopenia HITT heparin-induced thrombocytopenia with thrombosis HIV human immunodeficiency virus HLA human leukocyte antigens HME human monocytic ehrlichiosis HNCC hereditary nonpolyposis colorectal cancer HPA human platelet antigen HPV human papillomavirus HR hazard ratio; heart rate HRCT high-resolution computed tomography HSCT hematopoietic stem cell transplantation HSE herpes simplex encephalitis HSV herpes simplex virus HUS hemolytic uremic syndrome IA-2 islet antigen-2 antibody IBD inflammatory bowel disease IBS irritable bowel syndrome IBS-C irritable bowel syndrome with constipation IBS-D irritable bowel syndrome with diarrhea IBS-M mixed irritable bowel syndrome ICD implantable cardioverter defibrillator ICH intracerebral hemorrhage ICU intensive care unit IDSA Infectious Diseases Society of America IE infective endocarditis IGF-1 insulin-like growth factor-1 406 This document is licensed for individual use only. Copyright © 2018 American College of Physicians. All rights reserved. Abbreviations IgM anti-HAV IgM antibodies to hepatitis A virus IGRA interferon-γ release assay IM intramuscular INR international normalized ratio IPF idiopathic pulmonary fibrosis IPSS-R revised International Prognosis Scoring System IRIS immune reconstitution inflammatory syndrome ITP immune thrombocytopenic purpura IV intravenous IVC inferior vena cava JVD jugular venous distention KOH potassium hydroxide LABA long-acting β2-agonist LAC lupus anticoagulant LAM lymphangioleiomyomatosis long-acting muscarinic agent (also called LAMA long-acting anticholinergic agent) LBBB left bundle branch block LDH lactate dehydrogenase LDL low-density lipoprotein LES lower esophageal sphincter LFT liver function test lower gastrointestinal LGI luteinizing hormone LKM left lower quadrant LLO low-molecular-weight heparin LMWH lupus nephritis LN LP lumbar puncture LR likelihood ratio LTBI latent tuberculosis infection left ventricular LV LVAD left ventricular assist device left ventricular ejection fraction LVEF left ventricular hypertrophy LVH Mycobacterium avium complex MAC monoamine oxidase inhibitor MAOI mucosa-associated lymphoid tissue MALT mean arterial pressure MAP multifocal atrial tachycardia MAT mild cognitive impairment MCI MCP metacarpophalangeal mixed connective tissue disease MCTD mean corpuscular volume MCV myelodysplastic syndromes MDS multiple endocrine neoplasia type 1 MEN1 multiple endocrine neoplasia type 2 MEN2 metabolic equivalents METs myasthenia gravis MG monoclonal gammopathy of undetermined MGUS significance microhemagglutination assay for Treponema MHA-TP pallidum myocardial infarction MI MIBG metaiodobenzylguanidine measles, mumps, rubella MMR microscopic polyangiitis MPA myeloproliferative neoplasm MPN MPO myeloperoxidase MR mitral regurgitation magnetic resonance angiography MRA magnetic resonance cholangiopancreatography MRCP magnetic resonance imaging MRI MRSA methicillin-resistant Staphylococcus aureus MS multiple sclerosis MSSA methicillin-sensitive Staphylococcus aureus mTOR mammalian target of rapamycin MTP metatarsophalangeal MVP mitral valve prolapse N/A not applicable NAAT nucleic acid amplification testing NAFLD nonalcoholic fatty liver disease NASH nonalcoholic steatohepatitis NCCN National Comprehensive Cancer Network NET neuroendocrine tumor NMO neuromyelitis optica NNH number needed to harm NNT number needed to treat NOAC non-vitamin K antagonist oral anticoagulant NPH intermediate-acting insulin or Lente NPPV noninvasive positive-pressure ventilation NSAIDs nonsteroidal anti-inflammatory drugs NSCLC non–small cell lung cancer NSTE-ACS non–ST-elevation acute coronary syndrome NSTEMI non–ST-elevation myocardial infarction NYHA New York Heart Association OA osteoarthritis oral glucose tolerance test OGTT obstructive sleep apnea OSA peripheral arterial disease PAD pulmonary arterial hypertension PAH perinuclear antineutrophil cytoplasmic antibodies p-ANCA percutaneous coronary intervention PCI primary central nervous system lymphoma PCNSL polycystic ovary syndrome PCOS polymerase chain reaction PCR pulmonary capillary wedge pressure PCWP patent ductus arteriosus PDA phosphodiesterase type 4 PDE-4 phosphodiesterase type 5 PDE-5 pulmonary embolism PE positive end-expiratory pressure PEEP peak expiratory flow PEF polyethylene glycol PEG PET positron emission tomography platelet factor 4 PF4 PFO patent foramen ovale pulmonary function test PFT pulmonary hypertension PH pelvic inflammatory disease PID proximal interphalangeal PIP premenstrual dysphoric disorder PMDD PMN polymorphonuclear PMS premenstrual syndrome psychogenic nonepileptic seizures PNES paroxysmal nocturnal hemoglobinuria PNH by mouth PO PPI proton pump inhibitor proteinase 3 PR3 PrEP pre-exposure prophylaxis prostate-specific antigen PSA primary sclerosing cholangitis PSC prothrombin time PT PTH parathyroid hormone PTSD posttraumatic stress disorder peptic ulcer disease PUD PV polycythemia vera premature ventricular complex PVC rheumatoid arthritis RA receptor activator of nuclear factor kappa β RANK 407 This document is licensed for individual use only. Copyright © 2018 American College of Physicians. All rights reserved. Abbreviations RAST RBBB RBC R-CHOP radioallergosorbent test right bundle branch block red blood cell rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone RCT randomized controlled trial REM rapid eye movement RF rheumatic fever rVIIa recombinant factor VIIa RLQ right lower quadrant RNA ribonucleic acid RNP ribonucleic protein RPR rapid plasma reagin RR relative risk RRR relative risk reduction RTA renal tubular acidosis rTPA recombinant tissue plasminogen activator RUQ right upper quadrant RV right ventricular SAAG serum-ascites albumin gradient SABA short-acting β2-agonist SAH subarachnoid hemorrhage systolic blood pressure SBP squamous cell carcinoma SCC small cell lung cancer SCLC systemic exertion intolerance disease SEID sodium glucose transporter-2 SGLT2 syndrome of inappropriate antidiuretic hormone SIADH secretion small intestinal bacterial overgrowth SIBO systemic inflammatory response syndrome SIRS Stevens-Johnson syndrome SJS systemic lupus erythematosus SLE serotonin-norepinephrine reuptake inhibitor SNRI serum protein electrophoresis SPEP solitary pulmonary nodule SPN sulfosalicylic acid SSA systemic sclerosis SSC selective serotonin reuptake inhibitor SSRI ST-elevation myocardial infarction STEMI sexually transmitted infection STI superior vena cava SVC SVT supraventricular tachycardia free thyroxine T4 TAVR transcatheter aortic valve replacement TB tuberculosis TBI traumatic brain injury TBW total body weight Tdap diphtheria and reduced tetanus toxoids and acellular pertussis vaccine TEE transesophageal echocardiography TEN toxic epidermal necrolysis TIA transient ischemic attack TIBC total iron-binding capacity TIMI Thrombolysis in Myocardial Infarction (risk score) TIPS transjugular intrahepatic portosystemic shunt TLC total lung capacity TNF tumor necrosis factor TR tricuspid regurgitation TSH thyroid-stimulating hormone TSS toxic shock syndrome TST tuberculin skin testing TTE transthoracic echocardiography tTG tissue transglutaminase TTP thrombotic thrombocytopenic purpura UACS upper airways cough syndrome urine anion gap UAG UFH unfractionated heparin UGI upper gastrointestinal UPEP urine protein electrophoresis URI upper respiratory infection USPSTF United States Preventive Services Task Force UTI urinary tract infection VAP ventilator-associated pneumonia VDRL Venereal Disease Research Laboratory VEGF vascular endothelial growth factor VF ventricular fibrillation VKA vitamin K antagonist V/Q ventilation/perfusion ratio VSD ventricular septal defect VT ventricular tachycardia VTE venous thromboembolism vWD von Willebrand disease vWF von Willebrand factor VZV varicella-zoster virus WBC white blood cell WNNd West Nile neuroinvasive disease WNV West Nile virus WPW Wolff-Parkinson-White 408 This document is licensed for individual use only. Copyright © 2018 American College of Physicians. All rights reserved. Board Basics ® An Enhancement to MKSAP® 18 What’s Inside: • Don’t Be Tricked: incorrect answers that may masquerade as correct choices • Test Yourself: Abbreviated case histories found in Board exam questions, providing “word association” links to the correct answers • Study Tables: Key associations that tie concepts together to prepare you for related questions Plus other vital information to help you pass the Boards Board Basics e-book Go to for information about downloading the Board Basics e-book. This document is licensed for individual use only. Copyright © 2018 American College of Physicians. All rights reserved. You're Reading a Free Preview Pages 12 to 17 are not shown in this preview. You're Reading a Free Preview Pages 21 to 28 are not shown in this preview. You're Reading a Free Preview Pages 40 to 52 are not shown in this preview. You're Reading a Free Preview Pages 56 to 60 are not shown in this preview. You're Reading a Free Preview Pages 74 to 77 are not shown in this preview. You're Reading a Free Preview Pages 81 to 88 are not shown in this preview. You're Reading a Free Preview Pages 115 to 168 are not shown in this preview. You're Reading a Free Preview Pages 187 to 240 are not shown in this preview. You're Reading a Free Preview Pages 273 to 310 are not shown in this preview. You're Reading a Free Preview Pages 329 to 352 are not shown in this preview. You're Reading a Free Preview Pages 364 to 383 are not shown in this preview. You're Reading a Free Preview Page 387 is not shown in this preview. You're Reading a Free Preview Pages 391 to 408 are not shown in this preview. You're Reading a Free Preview Pages 412 to 416 are not shown in this preview.